Ertugliflozin to reduce arrhythmic burden in ICD/CRT patients (ERASe-trial) – A phase III study - 07/03/22
, Norbert J Tripolt, Dr. scient. med. b, Harald Sourij, MD b, Peter N Pferschy, BSc b, Abderrahim Oulhaj c, d, Hannes Alber, MD e, Marianne Gwechenberger, MD f, Martin Martinek, MD g, Sebastian Seidl, MD g, Deddo Moertl, MD h, Michael Nürnberg, MD i, Franz Xaver Roithinger, MD j, Clemens Steinwender, MD k, Markus Stühlinger, MD l, Andreas Zirlik, MD a, Martin Benedikt, MD a, Ewald Kolesnik, MD a, Markus Wallner, MD a, Ursula Rohrer, MD a, Martin Manninger, MD a, Daniel Scherr, MD aon behalf of the
ERASe study group
Background |
Sodium glucose cotransporter 2 (SGLT2) have proven profound positive effects in heart failure with reduced ejection fraction (HFrEF). These effects are independent from the presence of diabetes. Metabolic effects, antiinflammatory, and antifibrotic properties are discussed as underlying mechanisms. Despite a strong correlation of ventricular arrhythmias with HFrEF, the impact of ertugliflozin on the ventricular arrhythmic burden has not been investigated, yet. Therefore, the Ertugliflozin to Reduce Arrhythmic burden in ICD ± CRT patientS (ERASe) trial was designed to investigate the efficacy and safety of ertugliflozin in patients with reduced and midrange ejection fraction (EF) with or without diabetes.
Methods |
Within a multicentre, national, randomized, double-blind, placebo-controlled, phase 3b trial we aim to enrol a total of 402 patients across Austria. Patients with reduced or midrange EF and ICD ± CRT therapy >3 months and previous ventricular tachycardia (at least 10 documented VT episodes within the last 12 months) are randomized in a 1:1 ratio to ertugliflozin (5 mg once daily orally administered) or matching placebo. The primary endpoint of the ERASe trial is to investigate the impact of ertugliflozin on total burden of ventricular arrhythmias. Further objectives will include number of therapeutic interventions of implanted devices, atrial fibrillation and heart failure biomarkers.
Conclusion |
The ERASe trial will be the first trial to test ertugliflozin in heart failure patients with nonpreserved ejection fraction and ongoing ICD ± CRT therapy regardless of their diabetic status. The ERASe trial may therefore extend the concept of SGLT2 inhibition to improve cardiac remodelling, including reduced arrhythmic burden.
Trial registration Identifier EudraCT Nr. 2020-002581-14 / ClinicalTrials.gov Identifier: NCT04600921
Le texte complet de cet article est disponible en PDF.Plan
Vol 246
P. 152-160 - avril 2022 Retour au numéro
Article précédent
- Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial
- Connie N. Hess, Warren H. Capell, Michael R. Bristow, Wolfram Ruf, Michael Szarek, David A. Morrow, Jose C. Nicolau, Christopher A. Graybill, Debra Marshall, Judith Hsia, Marc P. Bonaca
- Early detection of obstructive coronary artery disease in the asymptomatic high-risk population: objectives and study design of the EARLY-SYNERGY trial
- Daan Ties, Paulien van Dorp, Gabija Pundziute, Carlijn M. van der Aalst, Jan Willem C. Gratama, Richard L. Braam, Dirkjan Kuijpers, Daniël D. Lubbers, Ivo A.C. van der Bilt, B. Daan Westenbrink, Martijn J. Oude Wolcherink, Carine J.M. Doggen, Ivana Išgum, Robin Nijveldt, Harry J. de Koning, Rozemarijn Vliegenthart, Matthijs Oudkerk, Pim van der Harst
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?